US Bancorp
IMDX

US Bancorp’s Insight Molecular Diagnostics IMDX Stock Holding History

US Bancorp’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25
Closed -$78 – 4095
2023
Q3 		$78 Hold
25
– – ﹤0.01% 3939
2023
Q2 		$115 Hold
25
– – ﹤0.01% 3937
2023
Q1 		$177 Hold
25
– – ﹤0.01% 4029
2022
Q4 		$161 Hold
25
– – ﹤0.01% 4076
2022
Q3 		$0 Hold
25
– – ﹤0.01% 4176
2022
Q2 		$0 Hold
25
– – ﹤0.01% 4169
2022
Q1 		$1K Hold
25
– – ﹤0.01% 3971
2021
Q4 		$1K Hold
25
– – ﹤0.01% 4008
2021
Q3 		$2K Hold
25
– – ﹤0.01% 3902
2021
Q2 		$3K Hold
25
– – ﹤0.01% 3745
2021
Q1 		$3K Hold
25
– – ﹤0.01% 3623
2020
Q4 		$1K Sell
25
-163
-87% -$5.98K ﹤0.01% 3688
2020
Q3 		$5K Buy
+188
New +$5.39K ﹤0.01% 3299

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

US Bancorp's IMDX Position: Q4 2023 in Review

US Bancorp sold out of Insight Molecular Diagnostics (IMDX) in Q4 2023, closing a stake of 25 shares — an estimated $78 sold.

US Bancorp first reported a position in IMDX in Q3 2020 and held it in 13 quarters. The position peaked at $5K in Q3 2020. 26 funds tracked by Wall St. Rank hold IMDX as of Q4 2023.

  • US Bancorp reported no remaining Insight Molecular Diagnostics position as of Q4 2023 after selling out during the quarter.
  • US Bancorp sold 25 Insight Molecular Diagnostics shares in Q4 2023, an estimated $78.
  • US Bancorp first reported a position in Insight Molecular Diagnostics in Q3 2020 and held it in 13 quarters.
  • US Bancorp's Insight Molecular Diagnostics position peaked at $5K in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2023.

Based on US Bancorp's 13F filing for Q4 2023, filed 9 Feb 2024.